These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana. Diphoko T; Gaseitsiwe S; Kasvosve I; Moyo S; Okatch H; Musonda R; Wainberg M; Makhema J; Marlink R; Novitsky V; Essex M AIDS Res Hum Retroviruses; 2018 Aug; 34(8):667-671. PubMed ID: 29732907 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. Llibre JM; Santos JR; Puig T; Moltó J; Ruiz L; Paredes R; Clotet B J Antimicrob Chemother; 2008 Nov; 62(5):909-13. PubMed ID: 18653487 [TBL] [Abstract][Full Text] [Related]
9. Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina. Córdova E; Loiza E; Porteiro N; Mingrone H Enferm Infecc Microbiol Clin; 2011; 29(6):428-31. PubMed ID: 21592625 [TBL] [Abstract][Full Text] [Related]
10. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807 [TBL] [Abstract][Full Text] [Related]
11. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M; Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623 [TBL] [Abstract][Full Text] [Related]
12. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection. Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of etravirine resistance in clinical samples by a simple phenotypic test. Agneskog E; Nowak P; Källander CF; Sönnerborg A J Med Virol; 2013 Apr; 85(4):703-8. PubMed ID: 23364785 [TBL] [Abstract][Full Text] [Related]
14. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana. Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264 [TBL] [Abstract][Full Text] [Related]
16. Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine. Theys K; Camacho RJ; Gomes P; Vandamme AM; Rhee SY; Clin Microbiol Infect; 2015 Jun; 21(6):607.e1-8. PubMed ID: 25704446 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA). Di Vincenzo P; Rusconi S; Adorni F; Vitiello P; Maggiolo F; Francisci D; Di Biagio A; Monno L; Antinori A; Boeri E; Punzi G; Perno CF; Callegaro A; Bruzzone B; Zazzi M; HIV Med; 2010 Sep; 11(8):530-4. PubMed ID: 20236364 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Lapadula G; Calabresi A; Castelnuovo F; Costarelli S; Quiros-Roldan E; Paraninfo G; Ceresoli F; Gargiulo F; Manca N; Carosi G; Torti C Antivir Ther; 2008; 13(4):601-5. PubMed ID: 18672539 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). Scherrer AU; Hasse B; von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Bucher HC; Ledergerber B; Günthard HF HIV Med; 2009 Nov; 10(10):647-56. PubMed ID: 19732174 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA). Rusconi S; Adorni F; Bruzzone B; Di Biagio A; Meini G; Callegaro A; Punzi G; Boeri E; Pecorari M; Monno L; Gianotti N; Butini L; Galli L; Polilli E; Galli M; Clin Microbiol Infect; 2013 Oct; 19(10):E443-6. PubMed ID: 23621421 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]